行情

CRMD

CRMD

CORMEDIX
AMEX

实时行情|Nasdaq Last Sale

3.190
+0.110
+3.57%
休市 16:00 04/03 EDT
开盘
3.020
昨收
3.080
最高
3.260
最低
3.000
成交量
22.14万
成交额
--
52周最高
10.76
52周最低
2.160
市值
8,334.47万
市盈率(TTM)
-1.7649
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CRMD价格均价为12.00,最高价位14.00,最低价为10.00。

EPS

CRMD 新闻

更多
  • Edited Transcript of CRMD earnings conference call or presentation 16-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 3天前
  • CorMedix, Inc. (NYSEMKT:CRMD) Just Reported Earnings, And Analysts Cut Their Target Price
  • Simply Wall St. · 03/20 11:32
  • Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%
  • Zacks · 03/19 15:40
  • What Did CorMedix, Inc.'s (NYSEMKT:CRMD) CEO Take Home Last Year?
  • Simply Wall St. · 03/19 12:19

所属板块

制药
-0.14%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

CRMD 简况

CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.
展开

微牛提供CorMedix Inc.(AMEX-CRMD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CRMD股票新闻,以帮助您做出投资决策。